Rapport Therapeutics Inc. Common Stock (RAPP)
Stock · NASDAQ · Health Care
$27.53as of 10/16/2026
Price chart
Active signals
High Beta42.0%
200 SMA Touch0.0%Resistance level
$38.52
Industry
Biotechnology: Pharmaceutical Preparations
RAPP Signal Track Record
How signals performed across all stocks →What RAPP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 14 | +6.6% | 57% | September 23, 2026 |
| Bollinger Band Breakout | 11 | -1.3% | 45% | August 6, 2026 |
| Bollinger Band Breakdown | 5 | +17.2% | 60% | September 23, 2026 |
| Any 20-session window (baseline) | +6.3% | 67% |
Computed by MarketWall from daily closing prices since March 26, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RAPP
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomol…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 84
- Website
- www.rapportrx.com/
Fundamentals
- 1-day range
- $26.93$29.75
- Market cap
- $2.22B
- P/E (trailing)
- —
- P/E (forward)
- -5.40
- EPS (trailing)
- $-3.04
- Dividend yield
- —
- Beta
- 1.80
- Avg. volume
- 350.8K
52-week range
$23.75$52.93
Next earnings: November 5, 2026 · EPS estimate $-1.22confirmed
Forecasts
15 analyst ratings
Buy 95%
Hold 5%
Sell 0%
1-year price forecast
High
$80
+190.6%
Median
$62
+125.2%
Low
$50
+81.6%
Rapport Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RAPPRapport Therapeutics Inc. Common Stock$27.57▼ 6.76%Market cap $2.22BP/E —$23.75$52.93
- URGNUroGen Pharma Ltd. Ordinary Shares$34.56▼ 5.60%Market cap $2.22BP/E —$16.37$50.81
- BHCBausch Health Companies Inc. Common Stock$6.3▼ 0.16%Market cap $2.21BP/E —$6.1$11.08
- MLYSMineralys Therapeutics Inc. Common Stock$20.3▼ 6.19%Market cap $2.23BP/E —$21.46$47.65
- PVLAPalvella Therapeutics Inc. Common Stock$120.3▼ 5.53%Market cap $2.23BP/E —$68.96$161.38
- SIONSionna Therapeutics Inc. Common Stock$3.89▼ 4.66%Market cap $2.24BP/E —$3.93$54.97
- HRMYHarmony Biosciences Holdings Inc. Common Stock$37.95▼ 0.84%Market cap $2.26BP/E 12.36$25.52$43.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RAPP Rapport Therapeutics Inc. Common Stock | $2.22B | — | $27.57 | ▼ 6.76% | $23.75$52.93 |
| URGN UroGen Pharma Ltd. Ordinary Shares | $2.22B | — | $34.56 | ▼ 5.60% | $16.37$50.81 |
| BHC Bausch Health Companies Inc. Common Stock | $2.21B | — | $6.3 | ▼ 0.16% | $6.1$11.08 |
| MLYS Mineralys Therapeutics Inc. Common Stock | $2.23B | — | $20.3 | ▼ 6.19% | $21.46$47.65 |
| PVLA Palvella Therapeutics Inc. Common Stock | $2.23B | — | $120.3 | ▼ 5.53% | $68.96$161.38 |
| SION Sionna Therapeutics Inc. Common Stock | $2.24B | — | $3.89 | ▼ 4.66% | $3.93$54.97 |
| HRMY Harmony Biosciences Holdings Inc. Common Stock | $2.26B | 12.36 | $37.95 | ▼ 0.84% | $25.52$43.49 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- UBS Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $71benzinga · 10/15/2026
- Guggenheim Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $65Benzinga · 10/6/2026
- Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating UpgradeSeekingAlpha · 9/24/2026
- The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' DataYahoo · 9/23/2026
- Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania - SlideshowSeekingAlpha · 9/23/2026
- The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and VaxcyteYahoo · 9/23/2026
- Rapport Therapeutics: Great CNS Science, But The Valuation Prices In Significant SuccessSeekingAlpha · 9/23/2026
- Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania TranscriptSeekingAlpha · 9/22/2026
- 4 Biotech Stocks With Key Clinical Readouts Expected This FallYahoo · 9/22/2026
Insider Activity
Insider Actions →Acquired
0
Disposed
100.2K
- Abraham Ceesay · October 7, 2026 · Sale1.1K @ $30.66
- Abraham Ceesay · October 6, 2026 · Sale3.4K @ $32.03
- Gault Cheryl · September 30, 2026 · Sale2.1K @ $33.76
- Gault Cheryl · September 30, 2026 · Sale7.9K @ $33.04
- Abraham Ceesay · September 23, 2026 · Sale43 @ $41.05
- Abraham Ceesay · September 23, 2026 · Sale215 @ $39.86
- Abraham Ceesay · September 23, 2026 · Sale2.0K @ $39.05
- Abraham Ceesay · September 8, 2026 · Sale1.1K @ $46.01
- Abraham Ceesay · September 8, 2026 · Sale7.1K @ $45.56
- Yeleswaram Krishnaswamy · August 25, 2026 · Sale16.2K @ $51.06
- Yeleswaram Krishnaswamy · August 25, 2026 · Sale20.8K @ $50.31
- Abraham Ceesay · August 25, 2026 · Sale18.9K @ $49.57
- Yeleswaram Krishnaswamy · August 24, 2026 · Sale13.2K @ $50
- Yeleswaram Krishnaswamy · August 19, 2026 · Sale404 @ $49.9
- Abraham Ceesay · August 11, 2026 · Sale5.8K @ $48.62
Institutional Ownership
March 31, 2026
- Total shares held
- 51.94M
- Total value held
- $1.58B
- Institutional holders
- 141
Top holders this quarter
- Unknown7.17M
- Unknown7.14M
- Unknown3.73M
- Unknown3.10M
- Unknown2.96M
- Unknown2.94M
- Unknown2.51M
- Unknown1.90M
- Unknown1.78M
- Unknown1.64M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Guggenheim initiates coverage of Rapport Therapeutics, sets $65 target
Guggenheim began coverage of Rapport Therapeutics and assigned a price target of $65. The target sits above the company's 52‑week high of $52.93, indicating a positive outlook. The stock currently trades with a low RSI and near a strong support level, which may influence market reaction to the new estimate.
Guggenheim initiates coverage of Rapport Therapeutics, sets $65 target. Guggenheim began coverage of Rapport Therapeutics and assigned a price target of $65. The target sits above the company's 52‑week high of $52.93, indicating a positive outlook. The stock currently trades with a low RSI and near a strong support level, which may influence market reaction to the new estimate.